700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Case Report Open Access
A 25 year old woman presenting with oligomenorrhoea was found to have a very high prolactin level. An MRI revealed a macroprolactinoma in the pitiutary gland. She was prescribed Cabergoline. However before the macroprolactinoma decreased in size she conceived. The patient was started with Cabergoline after the first trimester. She was observed with a careful history of headache, vomitings at each visit; periodic serum prolactin levels and visual field examinations. She had an uneventful course during pregnancy and delivered a healthy male baby. Cabergoline was stopped after delivery and she lactated the baby for six months. However she reported symptoms of head ache and an MRI diagnosed an expansion of the adenoma. Thereafter cabergoline was begun again and lactation was stopped in the interest of the mother. In this case cabergoline has been used to prevent tumour expansion in pregnancy and was found to be a safer, tolerable substitute to bromocryptine.
Macroprolactinoma, Cabergoline, Magnetic resonance imaging (MRI), Thyroid stimulating hormone (TSH), Macroprolactinoma, Cabergoline, Magnetic resonance imaging (MRI), Thyroid stimulating hormone (TSH)